Answers are grounded in this paper and cite their sources.
Background National estimates of the economic impact of clostridial diseases in Iranian livestock are limited. This study estimated the direct annual losses attributable to these diseases, assessed the modelled difference between expected and recorded losses in passive surveillance, and compared the economic performance of the current blanket vaccination programme with a targeted high-risk-area strategy. Methods We conducted a retrospective national economic-modelling analysis using secondary livestock-population data, Iranian Veterinary Organization (IVO) surveillance and vaccine-distribution records, published epidemiological evidence, and market-price information. Domestic programme and economic inputs were valued at September 2025 levels. Direct losses were calculated from species-specific mortality and emergency-slaughter estimates and species-specific animal values. A 10,000-iteration Monte Carlo simulation in R version 4.3.2 quantified uncertainty in selected parameters. Vaccine-procurement costs were based on the mean price obtained through enquiries to the Razi distribution cooperative network. Unavailable regional delivery and private animal-handling costs were not imputed; a uniform 20% surcharge was included only as an illustrative sensitivity scenario. Results Estimated direct annual losses from natural mortality and emergency slaughter were 13.56 trillion IRR (95% simulation interval: 10.96–16.25 trillion IRR; approximately US$13.56 million at the September 2025 exchange rate of 1 USD = 1,000,000 IRR), including approximately 99,815 natural deaths and 14,567 emergency slaughters. The model-based under-reporting ratio was approximately 122 (95% simulation interval: 98–146), indicating that recorded losses represented approximately 0.8% of modelled losses under the stated assumptions. After species-specific valuation, the procurement-only benefit-cost ratio (BCR) was 0.75 for the current blanket programme. The targeted base-case scenario had a procurement-only BCR of 1.74; this decreased to 1.45 with the illustrative 20% cost surcharge and to approximately 1.04 when both the conservative 50%-of-cases targeting assumption and the surcharge were applied. Conclusions The model indicates a substantial direct economic burden, although its exact magnitude remains uncertain because nationally representative Iranian necropsy-based attribution data and morbidity-related loss data are unavailable. Species-specific valuation reduces the estimated return from blanket vaccination compared with a pooled population-value approach. Risk-based vaccination may improve procurement resource use if the assumed concentration of disease in high-risk areas is confirmed and local delivery costs are measured. These findings support active surveillance and locally costed evaluation before any national reallocation of vaccination resources.
No takes yet. Share an insight, caveat, or question.
Baradaran‐Seyed et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: